ANI Pharmaceuticals, Inc. Forecast, price target & analysts
ANI Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
ANI Pharmaceuticals, Inc. Classifications & Recommendation:
ANI Pharmaceuticals, Inc. Price Target
| Target Price | $81.50 |
| Price | $69.36 |
| Potential |
17.50%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2026 .
The average ANI Pharmaceuticals, Inc. target price is $81.50.
This is
17.50%
register free of charge
$94.00
35.52%
register free of charge
$62.00
10.61%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2026 of
17.50%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 614.38 | 768.72 |
| 26.20% | 25.12% | |
| EBITDA Margin | 11.39% | 25.33% |
| 49.30% | 122.48% | |
| Net Margin | -3.58% | 5.74% |
| 187.67% | 260.55% |
8 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2025. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.04 | 2.09 |
| 210.64% | 300.96% | |
| P/E | 33.22 | |
| EV/Sales | 2.62 |
5 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
Current ANI Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
